NCT06836557

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

A Multicenter, Open Label, 3-Month Safety Study with Tradipitant in Patients with Idiopathic or Diabetic Gastroparesis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

Conditions

• Idiopathic Gastroparesis
• Diabetic Gastroparesis
• Gastroparesis

Interventions

Type	Name	Description
DRUG	Tradipitant	BID

Timeline

• Start date: 2024-01-09
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2025-02-20
• Last updated: 2025-02-20

Locations

3 sites across 2 countries: Belgium, Germany

Regulatory

• FDA-regulated drug study